Theragnostic Platform

AAA is a pioneer in the field of nuclear medicine theragnostics, with an expanding pipeline of theragnostic pairings for oncology indications. Theragnostics is a patient management strategy involving the integration of radiopharmaceutical diagnostics and therapeutics.

In the context of nuclear medicine, theragnostics refers to the use of targeting molecules labeled either with diagnostic radioisotopes, e.g., positron or gamma emitters, such as fluorine 18 (F 18) or gallium 68 (Ga 68), or with isotope used for therapeutics, e.g., alpha or beta emitters such as radium 223 (Ra 223), lutetium 177 (Lu 177) or actinium 225 (Ac 225) for diagnosis and therapy of a particular disease.

Our original theragnostic platform was based upon radiolabeling a targeting molecule, with high affinity for a receptor expressed on a tumor cell, with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy. We are now also exploring the use of other radioisotope combinations, including F 18 and Ac 225, among others. This approach enables molecular imaging and diagnosis of disease to be followed by a treatment utilizing the same molecular targets.

Using similar molecular targeting compounds in this manner also enables a more complete approach to patient management, because the diagnostic can then serve several simultaneous functions:

  • diagnosis,
  • staging/restaging,
  • monitoring,
  • selection for therapy using the same molecule labeled with a isotope used for therapeutics, or a different treatment course,
  • follow-up after treatment

For patients, theragnostics can lead to more effective care, selecting patients who would benefit the most from certain therapeutic interventions, while reducing or eliminating unnecessary treatment. This makes the theragnostic approach both efficient and patient-centric.

For physicians, theragnostics can enhance their ability to diagnose and stage disease, select optimal therapies, and monitor treatment response and disease progression, improving prognostic capability for better health outcomes.

For payors, theragnostic approaches can reduce costs associated with suboptimal diagnostics and treatments and shorten the time needed to diagnose and treat patients with effective individualized treatment plans.